These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38137913)

  • 1. Protocol for a Randomized, Open-Label Clinical Trial on the Effect of Mouthwash on Salivary SARS-CoV-2 Load.
    Konishi K; Onozuka D; Takatera S; Matsuo H; Yoshida H; Hamaguchi S; Yamamoto S; Sada RM; Suzuki K; Kutsuna S
    Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral mouthwashes for asymptomatic to mildly symptomatic adults with COVID-19 and salivary viral load: a randomized, placebo-controlled, open-label clinical trial.
    Onozuka D; Takatera S; Matsuo H; Yoshida H; Hamaguchi S; Yamamoto S; Sada RM; Suzuki K; Konishi K; Kutsuna S
    BMC Oral Health; 2024 Apr; 24(1):491. PubMed ID: 38664718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Cetylpyridinium Chloride mouthwash against SARS-CoV-2: A systematic review of randomized controlled trials.
    D'Amico F; Moro M; Saracino M; Marmiere M; Cilona MB; Lloyd-Jones G; Zangrillo A
    Mol Oral Microbiol; 2023 Jun; 38(3):171-180. PubMed ID: 36808889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial.
    Carrouel F; Viennot S; Valette M; Cohen JM; Dussart C; Bourgeois D
    Trials; 2020 Nov; 21(1):906. PubMed ID: 33138848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomized Clinical Trial.
    Alemany A; Perez-Zsolt D; Raïch-Regué D; Muñoz-Basagoiti J; Ouchi D; Laporte-Villar C; Baro B; Henríquez N; Prat N; Gianinetto MO; Gutiérrez MV; Sánchez-Paniagua MG; Henríquez NL; Vicente JM; Ara J; Rodriguez-Arias MA; Puig J; Blanco I; Lopez CC; Hernández Á; Bordoy AE; Redondo CE; Soler VG; Giménez M; Blanc V; León R; Gispert J; ; Clotet B; Izquierdo-Useros N; Mitjà O
    J Dent Res; 2022 Nov; 101(12):1450-1456. PubMed ID: 35727681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a Mouthwash Containing CHX and CPC in SARS-CoV-2-Positive Patients: A Randomized Controlled Clinical Trial.
    Bonn EL; Rohrhofer A; Audebert FX; Lang H; Auer DL; Scholz KJ; Schuster P; Wenzel JJ; Hiller KA; Buchalla W; Gottsauner JM; Vielsmeier V; Schmidt B; Cieplik F
    J Dent Res; 2023 Jun; 102(6):608-615. PubMed ID: 36942423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial.
    Eduardo FP; Corrêa L; Heller D; Daep CA; Benitez C; Malheiros Z; Stewart B; Ryan M; Machado CM; Hamerschlak N; Rebello Pinho JR; Bezinelli LM
    Heliyon; 2021 Jun; 7(6):e07346. PubMed ID: 34189331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of SARS-CoV-2 viral load in saliva after rinsing with mouthwashes containing cetylpyridinium chloride: a randomized clinical study.
    Bezinelli LM; Corrêa L; Beyerstedt S; Franco ML; Rangel ÉB; Benítez CG; Hamerschlak N; Pinho JRR; Heller D; Eduardo FP
    PeerJ; 2023; 11():e15080. PubMed ID: 38130922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS-CoV-2 viral load.
    Tarragó-Gil R; Gil-Mosteo MJ; Aza-Pascual-Salcedo M; Alvarez MJL; Ainaga RR; Gimeno NL; Viñuales RF; Fernández YM; Marco JM; Bolsa EA; Sancho JB; Cajo SA; Perez-Zsolt D; Raïch-Regué D; Muñoz-Basagoiti J; Izquierdo-Useros N; Pociello VB; León R; Peris DS
    J Clin Periodontol; 2023 Mar; 50(3):288-294. PubMed ID: 36345827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploratory study of drug concentration and inhibitory effect of cetylpyridinium chloride buccal tablets on SARS-CoV-2 infection among 10 Chinese subjects.
    Li Y; Xie Z; Chen L; Liu X; Li S; Ye S; Tang H; Lee C; Gu Q; Men F; Zhang J; Hu D; Jiang Y; Wang X; Wang Q; Feng Y; Niu S; Liu Y; Fang Y
    Fundam Clin Pharmacol; 2024 Jun; 38(3):579-587. PubMed ID: 37985697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.
    Carrouel F; Valette M; Gadea E; Esparcieux A; Illes G; Langlois ME; Perrier H; Dussart C; Tramini P; Ribaud M; Bouscambert-Duchamp M; Bourgeois D
    Clin Microbiol Infect; 2021 Oct; 27(10):1494-1501. PubMed ID: 34044151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eligibility and efficacy of a CPC- and CHX-based antiviral mouthwash for the elimination of SARS-CoV-2 from the saliva: A randomized, double-blind, controlled clinical trial.
    Brunello G; Wolf V; Kerberger R; Bernhard M; Lübke N; Becker J; Schwarz-Herzke B; Timm J; Becker K
    J Clin Periodontol; 2024 Feb; 51(2):158-166. PubMed ID: 38058254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the effect of gargling with hydrogen peroxide and povidone-iodine on salivary viral load of SARS-CoV-2: A pilot randomized clinical trial.
    Adl A; Sedigh-Shams M; Jamalidoust M; Rajabzadeh Z
    Niger J Clin Pract; 2023 Apr; 26(4):391-396. PubMed ID: 37203101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of mouthwash on reducing salivary SARS-CoV-2 viral load and clinical symptoms: a systematic review and meta-analysis.
    Zhang M; Meng N; Duo H; Yang Y; Dong Q; Gu J
    BMC Infect Dis; 2023 Oct; 23(1):678. PubMed ID: 37821800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva.
    Anderson ER; Patterson EI; Richards S; Pitol AK; Edwards T; Wooding D; Buist K; Green A; Mukherjee S; Hoptroff M; Hughes GL
    J Med Microbiol; 2022 Feb; 71(2):. PubMed ID: 35180046
    [No Abstract]   [Full Text] [Related]  

  • 18. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorhexidine mouthwash reduces the salivary viral load of SARS-CoV-2: A randomized clinical trial.
    Costa DD; Brites C; Vaz SN; de Santana DS; Dos Santos JN; Cury PR
    Oral Dis; 2022 Nov; 28 Suppl 2():2500-2508. PubMed ID: 34837305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial.
    Sánchez Barrueco Á; Mateos-Moreno MV; Martínez-Beneyto Y; García-Vázquez E; Campos González A; Zapardiel Ferrero J; Bogoya Castaño A; Alcalá Rueda I; Villacampa Aubá JM; Cenjor Español C; Moreno-Parrado L; Ausina-Márquez V; García-Esteban S; Artacho A; López-Labrador FX; Mira A; Ferrer MD
    Emerg Microbes Infect; 2022 Dec; 11(1):1833-1842. PubMed ID: 35796097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.